Related by context. All words. (Click for frequent words.) 72 Archexin 71 Vilazodone 70 Zoraxel 70 Pimavanserin 69 Lu AA# 69 Mipomersen 69 Serdaxin ® 68 AEGR 68 Carfilzomib 68 JAK inhibitor 68 tezampanel 68 Traficet EN 68 KRN# 68 HuMax CD# 68 otelixizumab 67 LibiGel ® 67 INCB# [001] 67 phase IIa clinical 67 torezolid phosphate 67 Tyrima 67 TRIOLEX 67 Bicifadine 67 Cethromycin 67 Synavive 66 SARMs 66 OHR/AVR# 66 vilazodone 66 oral prodrug 66 GLYX 66 MEK inhibitors 66 Panzem R 66 AZILECT R 66 Guanilib 66 R#/MEM # 66 Ophena TM 66 TRV# [001] 66 DDP# 66 MDV# 66 NGX# 66 investigational compound 66 HCV protease inhibitors 66 GFT# 66 PXD# 66 adipiplon 66 ProSavin 66 OncoVEX GM CSF 66 eprotirome 66 diabetic neuropathic pain 65 PRTX 65 Phase 2a trial 65 CCX# 65 CCR9 antagonist 65 Phase IIb trials 65 ozarelix 65 PRX # 65 Valdoxan 65 PEG SN# 65 tanespimycin 65 preclinically 65 XmAb# 65 ganetespib 65 Tasimelteon 65 HGS# 65 Panzem R NCD 65 Neurodex 65 Perifosine 65 Azedra 65 sodium glucose cotransporter 65 Triolex 65 INCB# [002] 65 metaglidasen 65 Ceflatonin R 65 Plicera 65 Aflibercept 65 Pirfenidone 65 Elesclomol 65 Milnacipran 65 Corlux 65 Rasagiline 65 vascular disrupting agent 64 HuLuc# 64 ISIS # 64 PRT# 64 CINQUIL 64 Aurexis 64 Anavex #-# 64 bicifadine 64 cannabinor 64 PSN# [002] 64 muraglitazar 64 BNC# 64 Catena ® 64 pomalidomide 64 Dapagliflozin 64 SCH # 64 investigational humanized monoclonal antibody 64 Golimumab 64 BZL# 64 LymphoStat B 64 Zoraxel TM 64 OMAPRO 64 Icatibant 64 Phase 2b Clinical Trial 64 Phenoptin 64 HQK 64 Amplimexon 64 Symadex 64 multi kinase inhibitor 64 anti amnesic 64 registrational trial 64 lurasidone 64 APOPTONE 64 Ambrisentan 64 BAY #-# 64 Tezampanel 64 CA4P 64 pharmacodynamic properties 64 Bezielle 64 MGCD# [001] 64 ELND# 64 NP2 Enkephalin 64 PD LID 64 ospemifene 64 Clonicel 64 Safinamide 64 RGB # 64 TBC# 63 HuMax EGFr 63 TACI Ig 63 selective modulator 63 talactoferrin 63 Phase 2a 63 Ceflatonin 63 AEG# 63 proteasome inhibitors 63 Elagolix 63 HuMax CD4 63 TELINTRA 63 Apoptone 63 TG# [003] 63 dimebon 63 ICA # 63 liposomal formulation 63 ZOLINZA 63 obatoclax 63 LY# [003] 63 alvimopan 63 ENMD # 63 Alzhemed TM 63 PDE4 inhibitor 63 ANAVEX #-# [003] 63 rNAPc2 63 vidofludimus 63 Locteron 63 MultiStem 63 INT# [002] 63 MAGE A3 ASCI 63 davunetide intranasal AL 63 dexpramipexole 63 S/GSK# 63 AZILECT ® 63 Talabostat 63 pertuzumab 63 Linaclotide 63 Ofatumumab 63 PS# [001] 63 Cetrorelix 63 mapatumumab 63 ONCONASE 63 Naproxcinod 63 Zoraxel ™ 63 RDEA# 63 mTOR inhibitor 63 Exelixis compounds 63 eltrombopag 63 axitinib 63 orally bioavailable 63 disease modifying 63 Azixa 63 vemurafenib 63 pradefovir 63 bosutinib 63 TREANDA 63 eniluracil 63 Restanza 63 Firazyr 63 preclinical efficacy 63 PF # [001] 63 FOLOTYN ® 63 Chemophase 63 forodesine 63 neuroprotective properties 63 ASONEP 63 URG# 63 delafloxacin 63 Tofacitinib 62 ACUROX ® 62 mertansine 62 refractory gout 62 KNS # 62 OXi# 62 Laquinimod 62 Nuvion 62 enzastaurin 62 TriRima 62 SRT# [003] 62 Amigal 62 Lacosamide 62 #ME# 62 Xanafide 62 Pagoclone 62 Rebif ® 62 6R BH4 62 EndoTAG TM -1 62 ularitide 62 radezolid 62 Iloperidone 62 CGEN # 62 leading oral taxane 62 elotuzumab 62 regorafenib 62 Omacetaxine 62 Q#IR 62 alvespimycin 62 Zolinza 62 HCV protease 62 Muraglitazar 62 safinamide 62 oral bioavailability 62 angiogenesis inhibitor 62 pegylated interferons 62 CoFactor 62 anticancer agent 62 Onconase 62 NUVIGIL 62 tiapamil 62 novel oral anticoagulant 62 CORLUX 62 HGS ETR1 62 lomitapide 62 NVA# 62 pseudobulbar affect PBA 62 Phase IIa trial 62 CTAP# Capsules 62 tolerability profile 62 samalizumab 62 teduglutide 62 visilizumab 62 EDEMA3 62 Silodosin 62 lintuzumab 62 R roscovitine 62 targeting CD# 62 Arimoclomol 62 ADAGIO study 62 Bendavia 62 pharmacological chaperone 62 virus HCV protease inhibitor 62 favorable pharmacokinetic profile 62 MoxDuo IR 62 dexanabinol 62 ALN TTR 62 PEGylated Fab fragment 62 efficacy tolerability 62 CRLX# 62 SAR# [004] 62 bardoxolone methyl 62 Adentri 62 Phase 1b trial 62 GSK# [002] 62 Tolvaptan 62 Tamibarotene 62 iroxanadine 62 Phase #/#a 62 mGluR2 NAM 62 Ocrelizumab 62 proteasome inhibitor 62 YONDELIS 62 Memryte 62 phase IIb clinical 62 Zalbin 62 antitumor activity 62 oral antiviral 62 DP b# 62 Homspera 62 reslizumab 62 nonclinical studies 62 lupus nephritis 62 Abiraterone acetate 62 Personalized Immunotherapy 62 registrational 62 Androxal ® 62 RG# [001] 62 anti EGFR antibody 62 trodusquemine 62 Glufosfamide 62 teriflunomide 62 atacicept 62 Zenvia ™ 62 velafermin 62 ASA# 62 betrixaban 62 tocilizumab 62 favorable tolerability 62 Ostarine 62 TRO# 62 CCR5 antagonist 62 Atiprimod 62 apremilast 62 eculizumab 62 Annamycin 62 IMA# 61 Zenvia Phase III 61 vosaroxin 61 CR# vcMMAE 61 SILENOR 61 Phase Ib study 61 therapeutic monoclonal antibody 61 orally administered inhibitor 61 baminercept 61 maximally tolerated dose 61 olanzapine Zyprexa 61 perifosine 61 Sym# 61 Interferon alpha 61 oral taxane 61 TAFA# 61 phase IIb 61 Nexavar ® 61 methylnaltrexone 61 Afatinib 61 Virulizin ® 61 NNR Therapeutics 61 sorafenib Nexavar 61 Nanobody 61 crofelemer 61 albinterferon alfa 2b 61 Phase IIa clinical 61 PREOS 61 Belimumab 61 Viramidine 61 investigational compounds 61 AAG geldanamycin analog 61 RhuDex ® 61 riociguat 61 Pazopanib 61 QNEXA 61 Meets Primary Endpoint 61 linaclotide 61 bifeprunox 61 Telaprevir 61 sunitinib malate 61 Benlysta belimumab 61 telcagepant 61 nitazoxanide 61 preclinical studies 61 VitiGam 61 Sapacitabine 61 CIMZIA TM 61 ruxolitinib 61 rasagiline tablets 61 cystinosis patients 61 Tarceva TM 61 Angiolix 61 Phase IIb Trial 61 Daclizumab 61 Rezular 61 Cardio Vascu Grow 61 DXL# 61 rilonacept 61 ZYBRESTAT 61 ALGRX 61 IMC A# 61 Azilect ® 61 rFVIIIFc 61 Oral NKTR 61 ELACYT 61 selective androgen receptor modulator 61 Syncria 61 masitinib 61 ocrelizumab 61 #D#C# 61 epigenetic therapies 61 zileuton 61 Zerenex 61 Revimmune 61 laquinimod 61 ALN TTR# 61 CYT# 61 cancer immunotherapies 61 HCD# [002] 61 TOLAMBA 61 Targretin 61 JAK1 61 tasimelteon 61 Civacir 61 novel VDA molecule 61 placebo controlled clinical 61 Viprinex 61 Hsp# inhibition 61 Aliskiren 61 edoxaban 61 mGluR5 NAM 61 systemically administered 61 ulimorelin 61 pharmacodynamic profile 61 MAP# 61 SERMs 61 deforolimus 61 L BLP# 61 JAK inhibitors 61 investigational therapies 61 IRX 2 61 CRMD# 61 TLK# 61 PEG PAL 61 Cethrin R 61 CCX# B 61 Entereg R 61 anidulafungin 61 dacetuzumab 61 Phase 2b clinical trials 61 casopitant 61 Menerba 61 bexarotene 61 Phase 2a clinical 61 Dimebon 61 Genz # 61 Zybrestat 61 IAP inhibitors 61 Xcytrin R 61 XL# XL# XL# 61 OMNARIS HFA 61 lumiliximab 61 CIPN 61 AZD# 61 SEROQUEL 61 Avanafil 61 ARCOXIA 61 Exelixis XL# 61 anticancer therapies 61 immunomodulatory 61 Desmoteplase 61 evaluating tivozanib 61 ataluren 61 CYCLOSET 61 XYOTAX TM 61 dextromethorphan quinidine 61 Pralatrexate 61 Hsp# inhibitors 61 picoplatin 61 Phase 2a Clinical Trial 61 Phase 2b study 61 Factor VIIa 61 ANAVEX #-# [001] 61 small molecule defensin 61 CBLC# 61 GALNS 61 PHX# 61 allosteric modulator 61 JAK2 inhibitor 61 ARRY 60 PEG Interferon lambda 60 Vidofludimus 60 RhuDex 60 Levetiracetam 60 oral anticoagulant 60 biologic therapy 60 Troxatyl 60 DermaVir Patch 60 orBec 60 class mGluR5 inhibitor 60 brivaracetam 60 Ridaforolimus 60 DAVANAT R 60 NEUGENE 60 investigational pan BCR 60 panitumumab Vectibix 60 generation purine nucleoside 60 GLPG# 60 BEMA Buprenorphine 60 amrubicin 60 Dasatinib 60 Perforomist ™ Inhalation Solution 60 Relovair 60 interferon gamma 1b 60 ATL/TV# 60 sapacitabine 60 mGluR2 positive 60 CDP# 60 Zingo TM 60 integrase inhibitor 60 Investigational Compound 60 tafamidis 60 MNTX 60 mGluR5 negative 60 desvenlafaxine 60 isoform selective 60 CG# [003] 60 Asentar 60 TMC# [002] 60 angiotensin receptor blocker ARB 60 cilengitide 60 Quinamed 60 TH# [003] 60 FM VP4 60 receptor tyrosine kinase inhibitor 60 YONDELIS R 60 Aplidin 60 alemtuzumab Campath 60 Shigamabs ® 60 iSONEP 60 Octreolin 60 Hsp# inhibitor 60 Dalbavancin 60 HGS ETR2 60 insulin sensitizer 60 KIACTA ™ 60 glucokinase activator 60 SNRI 60 phase Ib 60 Anidulafungin 60 MEK inhibitor RDEA# 60 Sphingomab 60 cardio renal 60 Phase IIb clinical 60 tolvaptan 60 selective androgen receptor modulators 60 voreloxin 60 antitumor effects 60 Tarvacin 60 phase IIb study 60 thymalfasin 60 Phase Ib clinical 60 2 methoxyestradiol 60 Angiocept 60 Preclinical studies suggest 60 Cancidas 60 DB# [003] 60 SNT MC# 60 Bortezomib 60 LymphoStat B belimumab 60 ixabepilone 60 TYZEKA 60 huC# DM4 60 intranasal formulation 60 R#/MEM 60 Hyphanox 60 diarrhea predominant irritable 60 phase IIa 60 Harbor BioSciences 60 ELND-#/AZD-# 60 pharmacokinetic PK study 60 epothilone 60 Thiovir 60 tolerability profiles 60 BENLYSTA ® 60 Arcalyst 60 BCX# 60 Reverset 60 Clofarabine 60 nalbuphine ER 60 prucalopride 60 investigational drug 60 paliperidone ER 60 Valortim 60 Nebido 60 DU #b 60 BAL# [002] 60 ANG# 60 AzaSite Plus 60 cariprazine 60 UPLYSO 60 Androxal 60 rFIXFc 60 REG1 60 Amrubicin 60 Surfaxin LS 60 Pyridorin 60 rHuPH# 60 oxypurinol 60 LymphoStat B TM 60 ADX# 60 EMBEDA ™ 60 tapentadol 60 nicotinic alpha 7 60 Microplasmin 60 NV1FGF 60 ibudilast 60 RE COVER 60 investigational monoclonal antibody 60 anti leukemic 60 arzoxifene 60 Vernakalant 60 MoxDuo 60 5 HT6 receptor 60 ALN PCS 60 partial agonist 60 tipranavir 60 PLX cells 60 Blinatumomab 60 antiviral activity 60 compound INCB# 60 Thiarabine 60 preclinical 60 Anthim 60 PDE# inhibitors 60 Ticagrelor 60 PNP inhibitor 60 Gaboxadol 60 Pivotal Phase 60 aclidinium 60 PEGylated interferon beta 1a 60 pimavanserin 60 mGlu2 3 60 Marqibo 60 Darinaparsin 60 COPAXONE R 60 lapatinib Tykerb 60 VAPRISOL 60 HCV protease inhibitor 60 Panzem 59 Pivotal Phase III 59 thetreatment 59 BCR ABL inhibitors 59 APD# 59 Myocet 59 Romidepsin 59 RoACTEMRA 59 Relivar 59 CORT # 59 Phase #b/#a 59 Æterna Zentaris 59 volociximab 59 DPX Survivac 59 incyclinide 59 mipomersen 59 Pafuramidine 59 nucleoside analog 59 dimebon latrepirdine 59 generation proteasome inhibitor 59 DAVANAT 59 TNF Tumor Necrosis Factor 59 dasatinib Sprycel ® 59 vascular disrupting agents 59 Ventavis 59 GSK# [001] 59 fosbretabulin 59 sulodexide 59 Sebivo 59 seliciclib CYC# 59 Tekamlo 59 systemic RNAi therapeutic 59 sorafenib tablets 59 Phase 2b trial 59 siRNA therapeutics 59 Saxagliptin 59 Nasulin 59 canakinumab 59 Fibrillex 59 Campath ® 59 romidepsin 59 J. Donald deBethizy 59 ramelteon 59 Telintra 59 perampanel 59 Sernova 59 Onbrez Breezhaler 59 BiTE 59 antithrombotic 59 Synavive ™ 59 PCK# 59 Phase Ib 59 Proxinium TM 59 multitargeted 59 Epanova 59 Phase 1a clinical 59 epothilones 59 BRAF inhibitor 59 NasalFent 59 Cannabinor 59 telbivudine 59 dirucotide 59 serotonin norepinephrine reuptake inhibitor 59 antiplatelet agent 59 glufosfamide 59 tamibarotene 59 iclaprim 59 oral Factor Xa 59 pharmacokinetic profile 59 Voreloxin 59 peripherally acting 59 ATL# [001] 59 Phase IIb Clinical Trial 59 teplizumab 59 Aganocide ® 59 Oracea TM 59 XL# [003] 59 ZYBRESTAT fosbretabulin 59 humanized monoclonal antibody 59 PEGylated anti 59 CYT# potent vascular disrupting 59 severe gastroparesis 59 acyclovir Lauriad R 59 Romiplostim 59 novel histone deacetylase 59 Phase 2b Trial 59 SILENOR TM 59 Randomized Phase 59 Insegia 59 AMPAKINE R 59 MBP# [001] 59 EDEMA4 59 mTOR kinase 59 Fx #A 59 tivozanib 59 ONCONASE R 59 lucinactant 59 ISENTRESS 59 injectable intravascular contrast 59 omacetaxine 59 SPRYCEL ® 59 Nanobody ® 59 tezampanel NGX# 59 Varespladib 59 atrasentan 59 dopamine partial agonist 59 zanolimumab 59 oral FTY# 59 Lubiprostone 59 ON #.Na 59 plasma kallikrein inhibitor 59 Gabapentin GR 59 Teplizumab 59 rALLy trial 59 Fidaxomicin 59 MAXY G# 59 PANVAC VF 59 ostarine 59 Tesetaxel 59 PROSTVAC TM 59 Phase Ib II 59 JANUVIA 59 ATHX 59 SinuNase 59 tolerability 59 liprotamase 59 humanized anti 59 receptor agonist 59 MabCampath 59 ACTEMRA TM 59 entinostat 59 mGluR5 antagonists 59 BEMA TM Fentanyl 59 QRxPharma 59 lasofoxifene 59 CIMZIA ™ 59 ACTEMRA 59 Celator 59 Imprime PGG 59 pralatrexate 59 temsirolimus 59 Chrysalin 59 OvaRex R 59 Phase III Clinical Trials 59 OMNARIS Nasal Spray 59 Oxytrex 59 PROVENGE sipuleucel T 59 Pradefovir 59 Vitaxin 59 Welchol 59 antisense drug 59 bardoxolone 59 neuraminidase inhibitor 59 Acapodene 59 LEVADEX ™ 59 SUTENT ® 59 palonosetron 59 asenapine 59 LY# [002] 59 DR Cysteamine 59 Kevetrin 59 cognitive impairment associated 59 mixed dyslipidemia 59 NKTR 59 Anticalin R 59 Phase 1b 59 orally administered 59 Phase #b/#a trial 59 Lupuzor 59 Behcet uveitis 59 urocortin 2 59 CINTREDEKIN BESUDOTOX 59 ELADUR 59 davunetide 59 anticancer compound 59 duloxetine Cymbalta 59 lorvotuzumab mertansine 59 XL# XL# XL# XL# 59 Anticalin ® 59 Eli Lilly Cymbalta 59 JP-#/fipamezole 59 DAVANAT ® 59 Fibrillex TM 59 Indaflex TM 59 candidate deforolimus 59 IL# PE#QQR 59 HspE7 59 Stedivaze 59 immunomodulating 59 antiangiogenic activity 59 Clolar ® 59 tramiprosate 59 Azedra TM 59 alagebrium 59 triglyceride lowering 59 Boceprevir 59 Phase #b/#a clinical 59 NTx TM -# 59 LEVADEX TM 59 bremelanotide 59 Elocalcitol 59 receptor agonists 59 relapsed SCLC 59 BioVant 59 GAMMAGARD 59 subcutaneous formulation 59 ganaxolone 59 omega interferon 59 Phase III Clinical Trial 59 heterozygous FH 59 PROCHYMAL 59 belinostat 59 systemic immunosuppressive drugs 59 IMGN# 59 topical NSAID 59 Stapled Peptide 59 Rivaroxaban 59 Bucindolol 59 Cethrin 59 tecarfarin 59 Exenatide LAR 59 renin inhibitor 59 LT NS# 59 ACZ# 59 gabapentin enacarbil 59 Alocrest 59 Ramoplanin 59 Oramed 59 ocular formulation 59 TPI ASM8 59 Onalta ™ 59 Epothilones 59 Phase IIa 59 selective kinase inhibitor 59 MAXY VII 58 SPC# [001] 58 Celgene Revlimid 58 AVN# [001] 58 ZFP Therapeutic 58 immunotherapeutic 58 CXB# 58 TKM ApoB 58 Paliperidone Palmitate 58 Aclidinium 58 Sanctura XR 58 Debio 58 vivo efficacy 58 Denufosol 58 cethromycin 58 elacytarabine 58 palifosfamide Zymafos TM 58 Prestara 58 DCCR 58 either acutely decompensated 58 GED aPC 58 LAF# 58 Tarvacin TM 58 Rasilez Tekturna 58 Evoltra 58 EFAPROXYN 58 Avicena 58 CRD5 58 oral isotype selective HDAC 58 highly selective inhibitor 58 Apixaban 58 TOCOSOL Paclitaxel 58 JAK Inhibitor 58 cathepsin K inhibitor 58 CRx 58 anticoagulant reversing agent 58 GRN# 58 CEQ# 58 Perforomist TM Inhalation Solution 58 Focalin XR 58 Lixivaptan 58 Rigel R# 58 sitaxsentan 58 fluoroquinolone antibiotic 58 Huntexil 58 IPLEX 58 IND submission 58 XL# anticancer compounds 58 Androxal TM 58 receptor inhibitor 58 schizophrenia CIAS 58 LHRH antagonists 58 opioid analgesic 58 Vertex telaprevir 58 docetaxel Taxotere ® 58 next generation URAT1 58 candidate CRLX# 58 Curaxin CBLC# 58 PLK1 SNALP 58 INC# 58 DOS# 58 blinatumomab 58 pharmacodynamic 58 vandetanib 58 Squalamine 58 Tanespimycin 58 myelofibrosis 58 fingolimod 58 radiation sensitizer 58 PROMACTA 58 formerly LymphoStat B 58 donepezil Aricept 58 AMR# 58 Saphris 58 Solazed TM 58 Alemtuzumab 58 febuxostat 58 ruboxistaurin 58 pharmacokinetic PK 58 agomelatine 58 vorinostat 58 Cimzia R 58 oral salmon calcitonin 58 cardiac toxicity 58 VA# [002] 58 BRIM2 58 Epratuzumab 58 ThGRF 58 SEROQUEL XR 58 Friedreich Ataxia FRDA 58 XP# XP# 58 Vicriviroc 58 MKC# MKC# PP 58 REMINYL ® 58 Elotuzumab 58 Simulect 58 Tovaxin 58 SUTENT 58 Bosutinib 58 Fabry Disease 58 Diamyd R 58 Delafloxacin 58 intranasal delivery 58 daclizumab 58 ponatinib 58 erlotinib Tarceva ® 58 selective orally bioavailable 58 Technosphere Insulin 58 BENLYSTA 58 rufinamide 58 tubulin inhibitor 58 lixisenatide 58 Tarceva erlotinib 58 histone deacetylase HDAC inhibitor 58 viral kinetics 58 bendamustine 58 tramiprosate Alzhemed TM 58 SLx 58 Locteron ® 58 MEK inhibitor 58 terlipressin 58 Bavituximab 58 IMC #B 58 IDX# 58 castrate resistant prostate cancer 58 Celebrex celecoxib 58 cMET 58 FTY# fingolimod 58 Keryx Biopharma 58 Crofelemer 58 AEZS 58 Ganetespib 58 icatibant 58 ImmunoVEX HSV2 58 roflumilast 58 analgesic efficacy 58 tolerated dose MTD 58 ATL# [002] 58 Temsirolimus 58 NEUMUNE 58 histone deacetylase inhibitor 58 Phase IIb 58 milnacipran 58 SYN#